Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms
Open accessThe DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
The incidence of chronic kidney disease (CKD) is increasing worldwide, with more than 26 million people suffering from CKD in the United States alone. More patients with CKD die of cardiovascular complications than progress to dialysis. Over 80% of CKD patients have hypertension, which is associated with increased risk of cardiovascular morbidity and mortality. Another common, perhaps underappreciated, feature of CKD is an overactive sympathetic nervous system. This elevation in sympathetic nerve activity (SNA) not only contributes to hypertension but also plays a detrimental role in the progression of CKD independent of any increase in blood pressure. Indeed, high SNA is associated with poor prognosis and increased cardiovascular morbidity and mortality independent of its effect on blood pressure. This brief review will discuss some of the consequences of sympathetic overactivity and highlight some of the potential pathways contributing to chronically elevated SNA in CKD. Mechanisms leading to chronic sympathoexcitation in CKD are complex, multifactorial and to date, not completely understood. Identification of the mechanisms and/or signals leading to sympathetic overactivity in CKD are crucial for development of effective therapeutic targets to reduce the increased cardiovascular risk in this patient group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Original record of muscle sympathetic nerve activity (MSNA) in a normal subject and a renal failure patient on hemodialysis, demonstrating significantly greater resting MSNA in the dialysis patient. The bottom two panels display a portion of the neurogram and simultaneous electrocardiogram from the patient on hemodialysis showing that the renal failure patient has a burst of MSNA with every cardiac cycle. (Modified from Converse et al. [11] with permission).](https://figures.cochat.ai/paper-figures/c29f315edad14e6d80676416128a09dc/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-1.jpg)
![Figure 2 Muscle sympathetic nerve activity (MSNA) expressed as burst frequency (bursts (bs)/min, A) and burst incidence (bs/100 heartbeats (hb), B) in subjects grouped according to their estimated glomerular filtration rate (eGFR), with the highest quartile of eGFR in group I and lowest quartile of eGFR in group IV. With decreasing eGFR, there is a significant and progressive increase in resting MSNA in chronic kidney disease (CKD) patients. * p < 0.05 significant difference between quartiles. (From Grassi et al. [13] with permission).](https://figures.cochat.ai/paper-figures/b4ac89c6b0474f7ca430dc2de3b4c6dc/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-2.jpg)
![Figure 3 Mean arterial pressure (MAP) responses during 8-h continuous systemic infusion of the nitric oxide synthase (NOS) inhibitor l-nitroarginine methyl ester (l-NAME) in rats with sympathectomy (open circles) and without sympathectomy (closed circles). Although no difference was observed in the initial increase in MAP (removal of endothelium-mediated dilation), sympathectomy attenuated the sustained hypertensive response to l-NAME, demonstrating a sympathetic contribution to the blood pressure raising effects of systemic NOS inhibition. * p < 0.05 vs. control. (From Sander et al. [75] with permission).](https://figures.cochat.ai/paper-figures/c4fa82d6798d4656876e51594ce8db56/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-3.jpg)
![Figure 4 Average mean arterial pressure, heart rate, and renal sympathetic nerve activity during continuous systemic infusion of asymmetric dimethylarginine (ADMA; an endogenous NOS inhibitor) in baroreceptor-intact (A) and baroreceptor-denervated animals (B). In comparison with barointact animals, barodenervated animals show a significant increase in renal SNA indicating frank sympathoexcitation in response to systemic ADMA infusion. * p < 0.05 vs. baseline; † p < 0.05 vs. baroreceptor intact. (From Augutyniak et al. [87] with permission.)](https://figures.cochat.ai/paper-figures/c6752938f9484a64b8856be4cf6b53c4/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-4.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Elevated sympathetic nerve activity is a hallmark of CKD104 that is evident even in the early stages of the disease and correlates inversely with estimated glomerular filtration rate (eGFR) and disease progression105.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [104]
In the citing paper
“The occur-rence of increased SNS activity in hypertension and CKD is well established83,162.”
From The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease (2018) · cites this paper as [162]
In the citing paper
“Modulation of the gut microbiota reduces systemic inflammation and SNS activity, both of which contribute to hypertension and CKD80,162,208.”
From The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease (2018) · cites this paper as [162]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895 · cited 1×
“More than 26 million people in the United States suffer from chronic kidney disease (CKD) with thousands of new cases diagnosed each year [1].”
Background(2010) · The Lancet · doi:10.1016/s0140-6736(10)60674-5 · Cited by 4,200 · cited 1×
“Moderate to severe CKD (stage 3–5) is associated with a significantly higher risk of cardiovascular (CV) morbidity and mortality [4,5].”
BackgroundAngiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., & Alexander, R. W. (1994) · Circulation Research · doi:10.1161/01.res.74.6.1141 · Cited by 2,735
A Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Physiological aspects of primary hypertension.
Folkow, B. (1982) · Physiological Reviews · doi:10.1152/physrev.1982.62.2.347 · Cited by 1,768
Böger, R. H., Bode-Böger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F., & Cooke, J. P. (1998) · Circulation · doi:10.1161/01.cir.98.18.1842 · Cited by 1,181
Cited by
The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease
Yang, T., Richards, E. M., Pepine, C. J., & Raizada, M. K. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0018-2 · Cited by 753
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Matsushita, K., Ballew, S. H., Wang, A. Y.-M., Kalyesubula, R., Schaeffner, E., & Agarwal, R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00616-6 · Cited by 670
Baaten, C. C. F. M. J., Vondenhoff, S., & Noels, H. (2023) · Circulation Research · doi:10.1161/circresaha.123.321752 · Cited by 243
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
Sano, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.12.004 · Cited by 188
Querfeld, U., MAK, R. H. K., & Pries, A. R. (2020) · Clinical Science · doi:10.1042/cs20200279 · Cited by 152
SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback
Upadhyay, A. (2024) · Kidney360 · doi:10.34067/kid.0000000000000425 · Cited by 167
“93 These observations indicate that SGLT2 inhibitors may partly be contributing to heart-kidney protection through the attenuation of sympathetic hyperactivity seen in CKD.”
BackgroundInfluentialEffect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
Scheen, A. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1165-1 · Cited by 122
Risk Factors of Chronic Kidney Disease Progression: Between Old and New Concepts
Mallamaci, F., & Tripepi, G. L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030678 · Cited by 195
“The sympathetic nervous system plays a crucial role in modulating arterial pressure [61], renal blood flow, and sodium balance [62].”
BackgroundPalmer, B. F. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.05.019 · Cited by 128
Shoemaker, J. K., Klassen, S. A., Badrov, M. B., & Fadel, P. J. (2018) · Journal of Neurophysiology · doi:10.1152/jn.00841.2017 · Cited by 93
Self-citationLi, N., Wang, Y., Wei, P., Yu, M., Yu, M., Zhou, G., Yuan, G., Sun, J., Dai, H., Zhou, E., et al. (2023) · Nutrients · doi:10.3390/nu15020360 · Cited by 90
“In addition, there is evidence that the harmful metabolites of disordered intestinal flora will stimulate the autonomic nervous system and then cause the excitation of sympathetic nerves, forming a vicious cycle between the brain–gut–kidney axis [47,48].”
BackgroundChronic kidney disease in the pathogenesis of acute ischemic stroke
Chelluboina, B., & Vemuganti, R. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19866733 · Cited by 88
Renal-Cardiac Crosstalk in the Pathogenesis and Progression of Heart Failure
Noels, H., van der Vorst, E. P. C., Rubin, S., Emmett, A., Marx, N., Tomaszewski, M., & Jankowski, J. (2025) · Circulation Research · doi:10.1161/circresaha.124.325488 · Cited by 103
“157 The activation of these pathways contributes to uremic cardiomyopathy and cardiovascular risk in CKD, at least partially also independent of blood pressure, as discussed in more detail in the following.”
Grassi, G. M., Biffi, A., Seravalle, G., Bertoli, S. V., Airoldi, F., Corrao, G., Pisano, A., Mallamaci, F., Mancia, G., & Zoccali, C. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002661 · Cited by 75
“Several causal factors are responsible for sympathetic overactivation in CKD, and these include high levels of angiotensin II, neural signals originating from the kidney that increase sympathetic outflow, reduced nitric oxide bioavailability and oxidative stress [42].”
BackgroundResultModulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling
Sussman, C. R., Wang, X., Chebib, F. T., & Torres, V. E. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109649 · Cited by 72
Renal Denervation to Treat Heart Failure
Sharp, T. E., & Lefer, D. J. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093431 · Cited by 59
Za’abi, M. A., Al‐Salam, S., Suleimani, Y. M. A., Manoj, P., Nemmar, A., & Ali, B. H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000488176 · Cited by 62
Sympathetic transduction in humans: recent advances and methodological considerations
Young, B. E., Greaney, J. L., Keller, D. M., & Fadel, P. J. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00926.2020 · Cited by 59
Self-citationPathophysiological concepts and screening of cardiovascular disease in dialysis patients
Echefu, G. C., Stowe, I., Burka, S., Basu‐Ray, I., & Kumbala, D. R. (2023) · Frontiers in Nephrology · doi:10.3389/fneph.2023.1198560 · Cited by 76
Veiga, A. C., Milanez, M. I. O., Ferreira, G. R., Lopes, N. R., Santos, C. P., De Angelis, K., Garcia, M. L., Oyama, L. M., Gomes, G. N., Nogueira, F. N., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002304 · Cited by 49
Increased cardiovascular risk in patients with chronic kidney disease
Vondenhoff, S., Schunk, S. J., & Noels, H. (2024) · Herz · doi:10.1007/s00059-024-05235-4 · Cited by 67
“These neurotransmitters can contribute to hypertension, vascular stiffness, and endothelial dysfunction [39].”
BackgroundXu, Z., Yang, S., Tan, Y., Zhang, Q., Wang, H., Tao, J., Liu, Q., Wang, Q., Feng, W., Li, Z., et al. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05379-9 · Cited by 75
Renal Sympathetic Nerve-Derived Signaling in Acute and Chronic Kidney Diseases
Noh, M. R., Jang, H., Kim, J., & Padanilam, B. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051647 · Cited by 52
“Accumulation of L-arginine analogues, NO synthase inhibitors, in CKD could potentially directly increase sympathetic nervous system (SNS) activity by inhibiting NO production [14].”
BackgroundThe sympathetic nervous system in heart failure revisited
Triposkiadis, F. K., Briasoulis, Α., Kitai, T., Magouliotis, D. E., Athanasiou, T., Skoularigis, J. S., & Xanthopoulos, A. V. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10345-y · Cited by 42
“Several studies have shown SNS overactivity in CKD [60].”
Renal nerves in physiology, pathophysiology and interoception
Evans, L. C., Dayton, A., & Osborn, J. W. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00893-3 · Cited by 46
“Elevated sympathetic nerve activity is a hallmark of CKD 104 that is evident even in the early stages of the disease and correlates inversely with estimated glomerular filtration rate (eGFR) and disease progression 105 .”
Chapman, C. L., Grigoryan, T., Vargas, N. T., Reed, E. L., Kueck, P. J., Pietrafesa, L. D., Bloomfield, A. C., Johnson, B. D., & Schlader, Z. J. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00374.2019 · Cited by 43
“Notably, there are also a number of states characterized by heightened basal sympathetic activity, including chronic kidney disease (24), type II diabetes (19), and obesity (18).”
BackgroundThe emotion paradox in the aging body and brain
Mather, M. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15138 · Cited by 45
Klimczak‐Tomaniak, D., Kuch, M., Pilecki, T., Żochowska, D., Wirkowska, A., & Pączek, L. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.10.008 · Cited by 37
“Moreover, NO was reported to act as an important inhibitor of sympathetic nervous system, a potent regulator of BP pattern.(44) All aforementioned processes play role in the development and persistence of arterial HT.”
BackgroundArcher, M., Dogra, N., Dovey, Z., Ganta, T., Jang, H., Khusid, J. A., Lantz, A. W., Mihalopoulos, M., Stockert, J. A., Zahalka, A. H., et al. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00755-6 · Cited by 44
“Downregulation of NO synthesis are prevented by prior administration of an α2adrenoceptor antagonist [130, 131] Administration of an α2-adrenoceptor agonist, B-TH933 to the denervated kidney restores both glomerular and tubular injury due to inhibition of NO [132].”
BackgroundKashioulis, P., Lundgren, J., Shubbar, E., Nguy, L., Saeed, A., Guron, C. W., & Guron, G. (2018) · Kidney & Blood Pressure Research · doi:10.1159/000491056 · Cited by 34
Beta2‐adrenergic receptor in kidney biology: A current prospective
Arif, E., & Nihalani, D. (2019) · Nephrology · doi:10.1111/nep.13584 · Cited by 32
Drew, R. C., Charkoudian, N., & Park, J. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00091.2019 · Cited by 33
“One major mechanism underlying increased cardiovascular risk in CKD is a chronic elevation of SNS activity (53).”
BackgroundVergaro, G., Aimo, A., Campora, A., Castiglione, V., Prontera, C., Masotti, S., Musetti, V., Chianca, M., Valleggi, A., Spini, V., et al. (2021) · Amyloid: Journal of Protein Folding Disorders · doi:10.1080/13506129.2021.1966624 · Cited by 25
“An activation of the sympathetic nervous system (SNS) and RAAS, never been investigated before in this setting, might provide a theoretical framework for the prescription of neurohormonal antagonists to patients with CA.”
InfluentialKelly, D., Kelleher, E. M., & Rothwell, P. M. (2025) · Stroke · doi:10.1161/strokeaha.124.047070 · Cited by 37
“46 Second, impaired para-sympathetic function in patients with CKD diminishes the anti-inflammatory effects mediated by the vagus nerve.”
Wu, L., Zhang, Y., Li, X., Du, X.-L., Gao, Y., Wang, J.-X., Wang, X., Chen, Q., Li, Y., Zhu, G., et al. (2022) · Antioxidants · doi:10.3390/antiox11051003 · Cited by 30
“Inhibition of sympathetic activity is a strategy for preventing hypertension and related complications [13] There is a close relationship between kidney and sympathetic hyperactivity in chronic kidney diseases and hypertension [14,15].”
BackgroundZoccali, C., Ortíz, A., Blumbyte, I. A., Rudolf, S., Beck‐Sickinger, A. G., Małyszko, J., Spasovski, G. B., Carriazo, S. M., Viggiano, D., Kurganaite, J., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab284 · Cited by 31
“Renal disease progression is a multifactorial problem and sympathetic overactivity is a well-documented risk factor for adverse renal outcomes [36, 54, 55].”
BackgroundPoulikakos, D. J., Hnatkova, K., Skampardoni, S., Green, D., Kalra, P. A., & Malík, M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00144 · Cited by 28
“Potential contributing underlying mechanisms of sympathetic overactivation in CKD (Kaur et al., 2017) include elevated angiotensin 2 levels (Siddiqi et al., 2009) that potentiate norepinephrine release from sympathetic nerve terminals, stimulation of afferent renal nerves and chemoreceptors by…”
BackgroundYe, C., Qiu, Y., Zhang, F., Chen, A., Zhou, Y., Wang, J., Chen, Q., Li, Y., Kang, Y., & Zhu, G. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00417-1 · Cited by 27
A Comparison of Hemodialysis and Peritoneal Dialysis in Patients with Cardiovascular Disease
Albakr, R. B., & Bargman, J. M. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.013 · Cited by 31
Hypertension in kidney transplant recipients
Alexandrou, M. E., Ferro, C. J., Boletis, I. N., Papagianni, A. A., & Sarafidis, P. A. (2022) · World Journal of Transplantation · doi:10.5500/wjt.v12.i8.211 · Cited by 33
Doiron, J. E., Li, Z., Yu, X., LaPenna, K. B., Quiriarte, H. D., Allerton, T. D., Koul, K., Malek, A. J., Shah, S. J., Sharp, T. E., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032646 · Cited by 26
Deus, L. A., Neves, R. V. P., Corrêa, H. D. L., Reis, A. L., Honorato, F. S., Silva, V. L., de Araújo, T. B., Souza, M. K., Sousa, C. V., Simões, H. G., et al. (2021) · Experimental Physiology · doi:10.1113/ep089341 · Cited by 29
“Both MPO and PON1 interfere with NO bioavailability (Marin et al., 2019), which would impact the regulation of the sympathetic outflow (Fontes et al., 2016; Kaur et al., 2017; Zablocki & Sadoshima, 2013).”
BackgroundComprehensive mapping of sensory and sympathetic innervation of the developing kidney
N'Guetta, P.-E., McLarnon, S. R., Tassou, A., Geron, M., Shirvan, S., Hill, R. Z., Scherrer, G., & O’Brien, L. L. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114860 · Cited by 30
“3,10,18 In contrast, the full complement and organization of kidney sensory nerves as well as their normal and pathophysiological roles remains poorly understood.”
Magvanjav, O., Cooper‐DeHoff, R. M., McDonough, C. W., Gong, Y., Segal, M. S., Hogan, W. R., & Johnson, J. A. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13429 · Cited by 28
Role of hypertension in kidney transplant recipients
Loutradis, C., Sarafidis, P. A., Marinaki, S., Berry, M., Borrows, R., Sharif, A., & Ferro, C. J. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00540-5 · Cited by 31
“Sympathetic nerve activity is already increased in the early stages of CKD and rises further with declining renal function, promoting increased peripheral vascular tone, as well as salt retention and ECF expansion [59, 60].”
BackgroundChou, Y., Huang, W., Chang, C., Yang, C. C. H., Kuo, T. B. J., Lin, S., Chiang, W., & Chu, T. (2018) · Nephrology · doi:10.1111/nep.13514 · Cited by 26
“All of aforementioned findings demonstrated that the changes of HRV in CKD patients were heterogeneous and were not all the same as previous concepts of depressed parasympathetic activity and increased sympathetic activity noted in late CKD stages.(21,22)”
ResultRenalase: a novel regulator of cardiometabolic and renal diseases
Vijayakumar, A., & Mahapatra, N. R. (2022) · Hypertension Research · doi:10.1038/s41440-022-00986-1 · Cited by 29
Autonomic brain functioning and age-related health concerns
Alrosan, A. Z., Heilat, G. B., Alrosan, K., Aleikish, A. A., Rabbaa, A. N., Shakhatreh, A. M., Alshalout, E. M., & Momany, E. M. A. (2024) · Current Research in Physiology · doi:10.1016/j.crphys.2024.100123 · Cited by 31
“For instance, long-term increases in SNS activity have been linked to hypertension (DeLalio et al., 2020), aortic and ventricular wall thickening (Borovac et al., 2020), endothelial dysfunction (Baqar et al., 2019), and renal failure (Kaur et al., 2017).”
BackgroundMunch, P. V., Christiansen, C. F., Birn, H., Erikstrup, C., & Nørgaard, M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16384 · Cited by 24
“12 donor nephrectomy may lead to elevated sympathetic and renin-angiotensinaldosterone system (RAAS) activity as well as hypervolemia, salt retention and endothelial dysfunction which are linked to increased risk of hypertension[20-22].”
BackgroundDalmasso, C., Leachman, J. R., Osborn, J. L., & Loria, A. S. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00079.2019 · Cited by 22
Renal denervation in the antihypertensive arsenal – knowns and known unknowns
Messerli, F. H., Bavishi, C., Brguljan-Hitij, J., Burnier, M., Dobner, S., Elijovich, F., Ferdinand, K. C., Kjeldsen, S. E., Laffer, C. L., Ram, C. V. S., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003171 · Cited by 23
“Hence, activation of the SNS, which occurs already in early stages of kidney diseases [95], plays a role in the development of hypertension and in chronic kidney disease (CKD) progression [96].”
BackgroundSoomro, Q. H., & Charytan, D. M. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000686 · Cited by 24
“Thus, in rats, Ang II microinjection into the RVLM causes dose dependent increases in arterial pressure via activation of excitatory areas of the vasomotor center [43,44].”
BackgroundHou, Y., Huang, C., Lu, C., Zheng, C., Lin, Y., Lu, K., Chung, Y.-L., & Chen, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.657794 · Cited by 21
Cardiovascular Risk and Its Presentation in Chronic Kidney Disease
Schunk, S. J., & Zimmermann, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134567 · Cited by 31
Nakano, T., Shiizaki, K., Miura, Y., Matsui, M., Kosaki, K., Mori, S., Yamagata, K., Maeda, S., Kishi, T., Usui, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55643-4 · Cited by 20
Qiu, Y., Zheng, F., Ye, C., Chen, A., Wang, J., Chen, Q., Li, Y., Kang, Y., & Zhu, G. (2020) · Neuroscience Bulletin · doi:10.1007/s12264-019-00460-y · Cited by 19
Baroreflex activation therapy systems: current status and future prospects
Seravalle, G., Dell’Oro, R., & Grassi, G. M. (2019) · Expert Review of Medical Devices · doi:10.1080/17434440.2019.1697230 · Cited by 20
Spirito, L., Manfredi, C., Carrano, R., Trinchieri, A., Salemi, F., Sciorio, C., Mirone, V. G., & Verze, P. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.07.014 · Cited by 20
Sleep Apnea as a Cardiorenal Risk Factor in CKD and Renal Transplant Patients
Zoccali, C., Roumeliotis, S. K., & Mallamaci, F. (2021) · Blood Purification · doi:10.1159/000513424 · Cited by 19
The Diabetic Cardiorenal Nexus
D’Elia, J. A., Bayliss, G. P., & Weinrauch, L. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137351 · Cited by 18
“Excessive sympathetic neuro-humoral activation has adverse consequences for both cardiovascular and renal function [81,216,217].”
BackgroundHonetschlägerová, Z., Škaroupková, P., Kikerlová, S., Husková, Z., Maxová, H., Melenovský, V., Kompanowska‐Jezierska, E., Sadowski, J., Gawryś, O., Kujal, P., et al. (2021) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2021.1907398 · Cited by 16
Zhang, Y., Wang, J., Xing, Y., Cui, C., Cheng, H., Chen, Z., Chen, H., Liu, C., Wang, N., & Chen, M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.890536 · Cited by 17
“This parameter has been widely used in cardiac arrhythmogenesis, acute myocardial infarction, sleep apnea, and neurologic recovery patients as a predictor of sympathetic tone (Kusayama et al., 2019; He et al., 2020; Chen et al., 2021; Kutkut et al., 2021; Liu et al., 2021).”
MethodPhysiological Mechanisms of Hypertension and Cardiovascular Disease in End-Stage Kidney Disease
Clemmer, J. S., Shafi, T., & Obi, Y. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01203-7 · Cited by 20
Nutraceuticals as a potential adjunct therapy toward improving vascular health in CKD
Kruse, N. T. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00152.2019 · Cited by 15
“Chronic overactivation of sympathetic nervous system activity (SNA) is also likely involved in the progression of vascular dysfunction in CKD (73).”
BackgroundNeurocirculatory regulation and adaptations to exercise in chronic kidney disease
Sprick, J. D., Jeong, J., Sabino‐Carvalho, J. L., Li, S., & Park, J. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00115.2023 · Cited by 15
Milanez, M. I. O., Silva, A. M., Perry, J. C., Faber, J., Nishi, E. E., Bergamaschi, C. T., & Campos, R. R. (2020) · Pharmacological Reports · doi:10.1007/s43440-019-00025-w · Cited by 12
Chronic Kidney disease and stroke: A Bi-directional risk cascade and therapeutic update
Chavda, V. K., Chaurasia, B. K., Deora, H., & Umana, G. E. (2021) · Brain Disorders · doi:10.1016/j.dscb.2021.100017 · Cited by 13
Chisty, T. T. E., Sarif, S., Jahan, I., Ismail, I. N., Chowdhury, F. I., Siddiqua, S., Yasmin, T., Islam, M. N., Khan, F., Subhan, N., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25057 · Cited by 16
“However, increased adrenergic stimulation is one of the major causes of chronic kidney impairment [29], the beneficial effect of L-CAR administration in such condition was not well studied and the mechanisms are little explained to date.”
BackgroundWu, L., Bo, J.-H., Zheng, F., Zhang, F., Chen, Q., Li, Y., Kang, Y., & Zhu, G. (2021) · Biomedicines · doi:10.3390/biomedicines9091118 · Cited by 12
Zanuzzi, M., Jeong, J., DaCosta, D. R., & Park, J. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00308.2023 · Cited by 10
Tsai, P.-C., Chao, Y., & Chan, J. Y. H. (2020) · The Chinese Journal of Physiology · doi:10.4103/cjp.cjp_85_20 · Cited by 10
Enhanced tyrosine sulfation is associated with chronic kidney disease-related atherosclerosis
Dai, D., Zhu, Z., Han, H., Xu, T., Feng, S., Zhang, W., Ding, F., Zhang, R., & Zhu, J. (2023) · BMC Biology · doi:10.1186/s12915-023-01641-y · Cited by 11
Ye, C., Zheng, F., Wang, J.-X., Wang, X., Chen, Q., Li, Y., Kang, Y., & Zhu, G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.673950 · Cited by 10
Davies, M. D., Sandoo, A., & Macdonald, J. H. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020026 · Cited by 12
“Finally, sympathetic nervous system (SNS) overactivity, which is common in patients with CKD [52], has been implicated as a potential contributor not only of CKD-related hypertension, but also of disease progression [53,54], possibly by damaging peritubular capillaries leading to ischaemia [55].”
BackgroundDoes SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Dimova, R. B., & Tankova, T. I. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1298-4205 · Cited by 12
“In the diabetic population, sympathetic nerve activity is primarily determined by afferent signals from the kidneys, which are richly innervated by chemoreceptors and baroreceptors that send signals to the brain [90].”
BackgroundNephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect
Mazzieri, A., & Marcon, L. M. R. (2025) · Biomedicines · doi:10.3390/biomedicines13092123 · Cited by 13
“SNS hyperactivity is known to be one of the potential mechanisms involved in the pathophysiology of hypertension [75,76].”
Cardiovascular autonomic neuropathy in chronic kidney disease: a study of kidney biopsy cases
Kuno, H., Kanzaki, G., Oba, R., Sasaki, T., Haruhara, K., Koike, K., Tsuboi, N., & Yokoo, T. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03879-2 · Cited by 7
Iliakis, P., Dimitriadis, K. S., Tatakis, F., Vakka, A., Sakalidis, A., Pyrpyris, N., Fragoulis, C., Konstantinidis, D., Aznaouridis, K. A., & Tsioufis, K. P. (2025) · Biomedicines · doi:10.3390/biomedicines13081951 · Cited by 10
“Assessing MSNA involves capturing bursts of spontaneous MSNA, in order to directly record the activity of post-ganglionic sympathetic nerve fibers that innervate vascular smooth muscle in skeletal muscle [52].”
Liu, S., Bian, R., Qian, Y., Liao, H., Gao, X., Zhang, Y., & Dong, W. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14605 · Cited by 9
Lavoie, M., Patel, J. A., & Camacho, M. (2019) · Sleep Medicine · doi:10.1016/j.sleep.2019.06.005 · Cited by 10
Peng, H., Liang, Z., Huang, B., Zhang, S., & Yang, Y. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1457984 · Cited by 6
Gollie, J. M., & Mahalwar, G. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2510365 · Cited by 9
Haris, M., Chen, C., Wu, J., Ramzan, M. N., Taj, A., Sha, S., Ullah, H., & Ma, Y. (2021) · Archives of Microbiology · doi:10.1007/s00203-021-02652-5 · Cited by 6
Bytyqi, V., Kannenkeril, D., Schmid, A., Striepe, K., Bosch, A., Karg, M. V., Schiffer, M., Uder, M., & Schmieder, R. E. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf184 · Cited by 7
“CKD is associated with SNS overactivity, which contributes not only to hypertension, but also to insulin resistance and impaired glucose metabolism [28 ].”
The effects of hemodialysis on the cardiovascular system
Pallister, Z. S., & Chung, J. (2024) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2024.10.001 · Cited by 5
Dimitriadis, K. S., Pitsiori, D., Alexiou, P., Pyrpyris, N., Sakalidis, A., Beneki, E., Iliakis, P., Tatakis, F., Theofilis, P., Tsioufis, P., et al. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001644 · Cited by 8
“16 Simultaneously, the RAAS upregulates central SNS activity because of the impaired expression of angiotensin type 1 and type 2 receptors, eventually leading to enhanced sympathetic activity.”
Limb-specific muscle sympathetic nerve activity responses to the cold pressor test
Coovadia, Y., Schwende, B. K., Taylor, C. E., & Usselman, C. W. (2023) · Autonomic Neuroscience · doi:10.1016/j.autneu.2023.103146 · Cited by 6
Nolde, J. M., Lugo‐Gavidia, L. M., Carnagarin, R., Azzam, O., Kiuchi, M. G., Mian, A. S., & Schlaich, M. P. (2021) · Physiological Reports · doi:10.14814/phy2.14996 · Cited by 4
“…(Badrov et al., 2016; Malliani & Montano, 2004), Takutsubo cardiomyopathy (Vaccaro et al., 2014), atrial fibrillation and sudden cardiac death (Kiuchi et al., 2019), sleep apnea (Floras, 2009), chronic kidney disease (Kaur et al., 2017; Schlaich et al., 2009), and obesity (Lambert et al., 2014).”
BackgroundSu, H., Wu, H., Wu, S.-B., & Zhou, M. (2023) · Acupuncture in Medicine · doi:10.1177/09645284231166718 · Cited by 4
Lv, Z., Fu, Y., Liu, C., Ma, Y., Yuan, M., Ren, J., & Gao, D. (2024) · iScience · doi:10.1016/j.isci.2024.109143 · Cited by 4
Zyubanova, I. V., Mordovin, V. F., Falkovskaya, А. Y., Pekarsky, S. E., Ripp, T. M., Manukyan, M. A., Lichikaki, V. A., Гусакова, А. М., Ryabova, T. R., & Baev, A. E. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4006 · Cited by 4
Monda, V. M., Porcellati, F., Strollo, F., Fucili, A., Monesi, M., Satta, E., & Gentile, S. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01791-x · Cited by 6
Burke, J., Pugh, D., Farrah, T. E., Hamid, C., Godden, E., MacGillivray, T., Dhaun, N., Baillie, J. K., KING, S. E., & MacCormick, I. J. C. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.11.19 · Cited by 5
Reyhanditya, D., Hikmawati, V. F., Kurnianingsih, N., & Fatchiyah, F. (2022) · Jurnal Kedokteran Brawijaya · doi:10.21776/ub.jkb.2022.032.01.1 · Cited by 4
Umezawa, M., Fujii, Y., Orito, K., & YOSHIMOTO, R. (2025) · Journal of Veterinary Medical Science · doi:10.1292/jvms.25-0040 · Cited by 7
“Although direct evidence is still lacking, Sano hypothesized that SGLT2 inhibitors may attenuate renal afferent signaling since several recent studies highlight the importance of renal afferent signals in the SNS overactivation [ 68, 70, 119].”
Neural Upregulation of SGLT2-MAP17-PDZK1 Complex in Kidneys of Rats With Heart Failure
Patel, T., Zheng, H., & Patel, K. P. (2026) · Hypertension · doi:10.1161/hypertensionaha.125.26077 · Cited by 3
Renalase Potential as a Marker and Therapeutic Target in Chronic Kidney Disease
Feier, L. F., Cuiban, E., Gogosoiu, E. B., Stepan, E., & Rădulescu, D. (2024) · Biomedicines · doi:10.3390/biomedicines12081715 · Cited by 3
“Among these, targeting the overstimulation of sympathetic activity in CKD has been less explored [8].”
BackgroundInfluentialLu, X., Guo, L., Sun, X., Fan, R., Wang, X., & He, Y. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04883-6 · Cited by 3
“Muscle sympathetic nerve activity rises early in chronic kidney disease and accelerates as glomerular filtration declines, even when resting blood pressure is still normal, underscoring its independence from tonic pressure load [37].”
Cooley, A. J., Savage, A., & Snowdon, C. T. (2021) · Veterinary Pathology · doi:10.1177/03009858211052664 · Cited by 3
Evaluation of cardiovascular risk in children with solitary functioning kidney
Sav, N. M., Köşger, P., Can, B., Çetin, N., Uçar, B., Alataş, Ö., Akyüz, F., & Yıldız, B. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02169-7 · Cited by 3
“It is thus understood that the damage starts even in the early stages of CKD in these patients.”
BackgroundInfluential
Metadata
- Authors
- Kaur, J., Young, B., & Fadel, P.
- Affiliations
- The University of Texas at Arlington (US)
- Corresponding author
- Fadel, Paul
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-08-02
- Volume
- 18
- Issue
- 8
- Pages
- 1682
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5578072
- OpenAlex
- W2741868536
- Cited by
- 168
- References
- 156
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 25 · 2023: 14 · 2022: 17 · 2021: 23 · 2020: 16 · 2019: 16 · 2018: 9 · 2017: 1
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (NIH R01 HL127071)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- chronic kidney disease, sympathetic nervous system, sympathoexcitation, sympathetic activity, hypertension, cardiovascular risk, chronic kidney disease progression, cardiovascular mortality, therapeutic target
- MeSH terms
- Animals, Humans, Hypertension, Renal, Sympathetic Nervous System, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.